COSMOS Pharmaceutical (3349) Q1 2025 earnings summary

Executive summary

• Net sales rose 8.4% year-over-year to ¥261,841 million for the three months ended August 31, 2024, driven by aggressive store expansion and cost control amid economic instability in Japan.

• Operating profit increased 28.8% year-over-year to ¥11,580 million, and profit attributable to owners of parent grew 25.1% to ¥8,143 million.

• The total number of stores reached 1,518 after opening 29 new stores and closing 1.

Financial highlights

• Gross profit improved to ¥54,562 million from ¥47,013 million year-over-year.

• Ordinary profit was ¥12,293 million, up 26.7% year-over-year.

• Basic earnings per share were ¥102.74, calculated assuming a 2-for-1 stock split.

• Comprehensive income reached ¥8,140 million, a 25.1% increase year-over-year.

Outlook and guidance

• Full-year net sales forecast is ¥1,037,000 million, up 7.5% year-over-year.

• Operating profit for the full year is projected at ¥31,600 million, with profit attributable to owners of parent at ¥24,500 million.

• Basic earnings per share forecast for the year is ¥309.12, reflecting the stock split.

• No change to the previously released financial results forecast.